VoxCell engineers 3D bioprinted, vascularized human tissue models to enhance preclinical drug discovery. These physiologically relevant microphysiological systems mimic in-vivo microenvironments, offering predictive insights superior to traditional animal models. The functional microvascular networks enable realistic drug delivery and distribution studies for improved therapeutic development.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods often rely on animal models or simplistic cell cultures that fail to accurately replicate human tissue complexity and microenvironment. This leads to inaccurate predictions of drug distribution and efficacy, resulting in costly late-stage failures in clinical trials.
Solution
VoxCell develops bioprinted tissue models that mimic human tissue structures, including advanced vasculature, to provide more predictive drug distribution and efficacy data during preclinical trials. Their platform utilizes customizable bioinks and in-house software to generate human-like vessel models tailored to specific research needs. By screening candidate compounds in these tissue models, researchers can obtain translatable data that enhances the accuracy of therapeutic assessments and accelerates the preclinical pathway.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in preclinical drug discovery and development.
Features
- Customizable bioinks designed to replicate the extracellular matrix of soft living tissues
- Generation of advanced, human-like vasculature within bioprinted tissue models
- In-house software for designing and optimizing vessel structures
- Screening assays to evaluate drug distribution and efficacy in a human-relevant context
- Predictive data that reduces the risk of late-stage clinical trial failures